Article Text

Download PDFPDF
Systemic Meloxicam Reduces Tactile Allodynia Development After L5 Single Spinal Nerve Injury in Rats
  1. Masahiro Takahashi, M.D.,
  2. Masahiko Kawaguchi, M.D.,
  3. Keiji Shimada, M.D.,
  4. Toshikatsu Nakashima, M.D., Ph.D. and
  5. Hitoshi Furuya, M.D.
  1. From the Department of Anesthesiology, Nara Medical University, Nara, Japan; Department of Pathology, Nara Medical University, Nara, Japan; Department of Physical Therapy, Faculty of Health Science, Kio University, K.-Ryotown, Nara, Japan.
  1. Reprint requests: Masahiro Takahashi, M.D., Department of Anesthesiology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan. E-mail: masakun{at}nmu-gw.naramed-u.ac.jp.

Abstract

Background Although recent evidence suggests that cyclooxygenase-2 (COX-2) may contribute to the development and management of neuropathic pain, the efficacy of COX-2 inhibitor against neuropathic pain is still unclear. In this study, we investigated the effects of the systemic administration of the selective COX-2 inhibitor meloxicam at an early stage after nerve injury on the development of tactile allodynia in L5 single spinal-nerve injury in rats.

Methods Twenty-four young male Sprague-Dawley rats received L5 single spinal-nerve injury. Nerve-injured rats (6 per group) received repeated intraperitoneal administrations of meloxicam (1, 2, or 4 mg/kg) or vehicle 0, 12, 24, and 36 hours after nerve injury. Tactile allodynia was quantified for 4 weeks by use of von Frey filaments.

Results In animals given 2 mg/kg and 4 mg/kg, hind-paw withdrawal thresholds 4 weeks after nerve injury were significantly higher compared with those of the vehicle-treated animals. The area under the time-effect curve from preinjury to 4 weeks after nerve injury values were significantly higher in animals treated with 4 mg/kg of meloxicam compared with animals treated with vehicle.

Conclusion Systemic administration of 2 mg/kg and 4 mg/kg of meloxicam at an early stage after nerve injury attenuated the development of tactile allodynia. These results suggest that COX-2 may be at least in part involved in the development of tactile allodynia in an L5 single spinal-nerve injury model.

  • COX-2 selective inhibitor
  • Meloxicam
  • Neuropathic pain
  • Tactile allodynia development
  • Spinal-nerve injury

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • This work received financial support from Boeringer Ingelheim Co., Ltd.

    This work presented in ASA 2003 in San Francisco.